PT Etana Biotechnologies Indonesia has secured an undisclosed Series B funding round led by Yunfeng Capital while Thailand securities company InnovestX Securities Co has launched a digital investment app.
Etana raises Series B funding round
PT Etana Biotechnologies Indonesia, an Indonesian biopharmaceutical company, has secured an undisclosed Series B funding round led by Yunfeng Capital for new product licensing, hiring manpower and capacity expansion.
Yunfeng Capital is a Shanghai-based private equity firm founded in 2010 by Alibaba’s Jack Ma and Target Media’s David Yu. The round was also joined by Highlight Capital.
Founded in 2014, Etana produces biopharmaceuticals for various diseases, including autoimmune and cancer. The company recently made headlines for spearheading the production of mRNA COVID-19 vaccines in the country.
Etana is backed by Legend Capital, UOB Venture Management Pte Ltd, Innovent Biologics and China Medical System Holdings Limited, according to its website.
InnovestX Securities launches app
Thailand securities company InnovestX Securities Co, formerly known as SCB Securities (SCBS), has launched a digital investment app called InnovestX, which offers domestic and international equities, mutual funds, bonds and digital assets.
It aims to work with the SCBX group of companies that will provide investment financial infrastructure and a suite of digital asset services. InnovestX aims to go public with a goal of 4-5 million customers within three years.
The company called the app Thailand’s first super-app for investing as it offers several asset classes on one platform. By opening a single account, customers will be able to invest in all assets. When it comes to digital assets, InnovestX is connected to key partner exchanges such as FTX, Coinbase and Bitkub.
InnovestX is the only securities company in Thailand that has both securities and digital asset brokerage licences.